GALECTIN THERAPEUTICS INC 8-K

What Happened
Galectin Therapeutics Inc. filed a Form 8-K on March 17, 2026 (Item 5.02) announcing that on March 12, 2026 the Board appointed Dr. Henry Brem as a director, effective immediately. The filing states Dr. Brem was not appointed pursuant to any arrangement or understanding with any other person and there are no transactions between him and the company reportable under Item 404(a) of Regulation S-K. At the time of appointment he will not serve on any Board committees and will be paid under the company’s standard non-employee director compensation program as described in the company’s most recent proxy.

Key Details

• Appointment date: March 12, 2026; disclosed in 8-K filed March 17, 2026 (Item 5.02).
• No reportable related-party transactions identified under Item 404(a).
• No committee assignments at time of appointment; compensation per standard non-employee director program.
• Dr. Brem’s background: Henry Brem Professor of Neurosurgery at Johns Hopkins, former Director of Johns Hopkins Neurosurgery (2000–2025), co‑director of a brain cancer program, inventor of localized drug-delivery approaches (e.g., Gliadel®), 416+ peer‑reviewed papers, multiple patents, long‑standing NIH funding, and member of the National Academy of Medicine.

Why It Matters
This filing documents a board-level appointment of an experienced neurosurgeon‑scientist with extensive translational and oncology credentials. The 8-K does not disclose any immediate financial impact, related-party transactions, or new compensation arrangements beyond the company’s standard director program. Investors should note the addition for corporate governance and scientific expertise context; any future material changes (committee assignments or additional compensation) would be reflected in subsequent filings.